Frazier Healthcare Partners Private Equity Firm Overview

Frazier Healthcare Partners is a private equity firm that focuses on investing in the healthcare industry. They have a dedicated team with a strong track record of success.

The firm was founded in 2005 by Eric M. Hansen and Scott C. Roberts. Frazier Healthcare Partners is headquartered in Seattle, Washington.

Frazier Healthcare Partners has a robust investment strategy, focusing on transformative healthcare companies. They have made 335 investments across various sectors, including biopharmaceutical services, medical and clinical trial services, and drug development providers.

Their investment profile typically involves equity commitments ranging from $30 million to $350 million for fast-growing, low- to middle-market healthcare companies with EBITDA of $5-50 million. They also provide a range of services to their portfolio companies, including human capital, financial services, operation management, legal, and information technology services.

Here are some key statistics about their investments and portfolio exits:

Frazier Healthcare Partners has also had 106 portfolio exits, with their latest exit being the acquisition of Critical Insight by Lumifi Cyber on November 5, 2024.

Frazier Healthcare Partners has a robust investment strategy in place, focusing on the healthcare industry. They have a four-stage process for making investments, starting with idea generation through proactive outreach and bi-annual retreats.

Their investment profile is quite specific, with equity commitments ranging from $30-350 million in fast-growing, low- to middle-market healthcare companies. These companies typically generate EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of $5-50 million.

In partnership with its network and human capital team, Frazier pairs qualified executives with curated investment ideas. This is known as the Executive in Residence (EIR) program. The EIR also benefits by taking on an Executive Chairman or CEO role.

Frazier’s Center of Excellence team provides a range of services to its portfolio companies, including human capital, financial services, operation management, legal, and information technology services. This support helps portfolio companies scale and succeed.

Frazier has made 335 investments, with their latest investment being in MBX Biosciences as part of their Series C on August 05, 2024. They have a strong track record of investing in the healthcare industry.

Here are some of the companies in Frazier's portfolio:

Frazier's investment in RevSpring, a leading provider of end-to-end communication and payment solutions, demonstrates their focus on transformative healthcare companies.

Frazier Healthcare Partners has a impressive track record of portfolio exits, with 106 successful exits under their belt. Their latest exit was Critical Insight, acquired by Lumifi Cyber on November 5, 2024.

One notable exit was MBX Biosciences, which went public on September 13, 2024, raising a significant amount of capital. Alcresta Therapeutics was also acquired by Linden Capital Partners on March 12, 2024.

The types of exits Frazier Healthcare Partners has made are quite diverse, with a mix of acquisitions, IPOs, and secondary sales. In fact, their portfolio exits have a total value of $3.9 billion, with a significant portion coming from trade sales to public companies.

Here's a breakdown of the types of exits Frazier Healthcare Partners has made:

IPOs have been a relatively rare occurrence in Frazier Healthcare Partners' portfolio exits, making up only 19% of their total exits. However, when they do happen, they can be very lucrative, as seen in the case of MBX Biosciences.

Frazier Healthcare Partners has a strong focus on life sciences, with a $617 million life sciences-focused fund raised in 2020. This fund invests in transformative companies that develop novel therapeutics.

Their Life Sciences team invests in three main areas: company formation, early-stage venture, and late private/publics. They identify innovative startup companies with incredible management teams and provide guidance, resources, and expertise at every stage of their business development.

Some notable investments include Acerta Pharma, which was acquired by AstraZeneca in 2016, and Dascena, which uses advanced machine learning to improve patient care. The team also invests in companies like Marcadia Biotech, which uses incretin pathways to treat type 2 diabetes.

Here are some of the companies Frazier Life Sciences team has invested in:

In addition to life sciences, Frazier Healthcare Partners has also made a significant investment in communications and payment solutions through the acquisition of RevSpring.

Frazier Healthcare Partners has made 335 investments, with their latest investment being in MBX Biosciences as part of their Series C on August 05, 2024.

They have a growth buyout team that adheres to four stages while making investments in medical products, biopharmaceutical services, and other related sectors. These stages include idea generation, investment profile, executive in residence, and center of excellence team.

The growth buyout team makes equity commitments from $30-350 million in fast-growing, low- to middle-market healthcare companies, generating EBITDA of $5-50 million. Investments come in the form of company buyouts, carveouts, and recapitalizations.

Frazier Healthcare Partners has acquired 23 companies, with their latest acquisition being DirectMed Imaging on October 15, 2024. The valuation of DirectMed Imaging's acquisition is $XXM.

Here is a list of Frazier Healthcare Partners' acquisitions:

The partnership with Frazier will leverage Frazier’s investment, experience, and deep industry expertise to accelerate the Company’s success as a leading solution provider in the communication and payments industry.

The Frazier Life Sciences Team is a group of specialists who invest in and form companies that develop, commercialize, and license novel therapeutics.

They hold a $617 million life sciences-focused fund, raised in 2020, to invest in transformative companies.

Their investment strategy focuses on three areas: company formation, early-stage venture, and late private/publics.

Here are some examples of companies they've invested in:

Frazier Healthcare Partners has a diverse portfolio of companies that cater to various needs in the healthcare industry. They invest in transformative healthcare companies that provide services such as biopharma services, medical and clinical trial services, and drug development providers.

One of the companies in their portfolio is Alteon Health, which offers outsourced healthcare practice management services to hospitalist programs, emergency departments, and urgent care centers. These services aim to improve patient experience and physician satisfaction.

Another company is Caravel Autism Health, which provides home-based therapies to children suffering from autism or related developmental disabilities. Their services include diagnosis and evaluation, therapy, and treatment, as well as social skills training.

Their portfolio also includes EPTAM Precision, a leading outsourced manufacturer in the medical device industry, with expertise in metal machining, plastic machining, and component design.

Frazier's growth funds also invest in Leiters, a manufacturer and provider of compounded sterile products registered by the FDA. Their products include ophthalmic products and acute setting injectables.

Here are some of the companies included in their portfolio:

Frazier Healthcare Partners has acquired 5 companies in the last 3 years. They have a strong focus on investing in transformative healthcare companies.

The firm's most common sectors for investment are life science (36%) and healthcare services (34%). This indicates a clear direction in their investment strategy.

Frazier Healthcare Partners has invested in 19 US states and 2 different countries. This demonstrates their commitment to expanding their reach and impact.

Their most common exit type is trade sale (45%), which suggests they often find success in selling their investments to other companies. In 2022, they sold Parata Systems for $1.5B, their largest disclosed exit.

Here's a breakdown of Frazier Healthcare Partners' most common investment types:

This information provides insight into Frazier Healthcare Partners' investment approach and highlights their focus on growth and expansion.

Frazier Healthcare Partners has a SIC code of 283 and 28.

The SIC code is a unique identifier for a company's industry classification.

Frazier Healthcare Partners is classified under this code, indicating its involvement in the pharmaceutical and medicine manufacturing sector.

This code can be useful for research and analysis purposes, providing a standardized way to categorize companies.

Knowing a company's SIC code can also help with market research and competitor analysis.

A company's SIC code can often be found in public records and databases.